Relapsed or Refractory Acute Myeloid Leukemia
Conditions
Brief summary
This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
Detailed description
Main Purpose： To observe the efficacy of selinexor in combination with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia :complete remission rate (CR rate), partial remission rate (PR rate), no remission rate (NR rate), complete remission with incomplete hematologic recovery(CRi rate) Secondary Purposes： 1. To observe the recurrence rate of selinexor combined with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia, treatment-related mortality(TRM), Overall Survival (OS), Event-Free Survival (EFS); 2. Safety indicators: to observe adverse events and deaths during treatment with selinexor in combination with HAD or CAG regimen.
Interventions
DRUGSelinexor
Given PO
Given per standard of care
DRUGDaunorubicin
Given per standard of care
DRUGCytarabine
Given per standard of care
DRUGGranulocyte Colony-Stimulating Factor
Given per standard of care
DRUGAclacinomycin
Given per standard of care
Sponsors
Antengene Corporation
Shanxi Bethune Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Age:18-60 years old; 2. Except for patients with AML-M3 with acute myeloid leukemia； 3. Meet the diagnostic criteria for refractory AML (2011 Chinese guidelines for the diagnosis and treatment of acute myeloid leukemia (relapsed or refractory)):(1) The standard regimen did not achieve complete remission after 2 courses of induction chemotherapy;(2) Relapse within 6 months after the first complete remission; (3) Patients who relapse after 6 months after the first complete remission, and those who fail to induce chemotherapy after the original program; (4) 2 or more recurrences; (5) Extramedullary leukemia persists； 4. Meet the diagnostic criteria for recurrent AML (refer to the 2014 NCCN guidelines): after complete remission, (1) naive cells appear in peripheral blood; (2) \>5% of bone marrow naive cells; (3) Extramedullary recurrence； 5. The bone marrow image indicates active hyperplasia or hypoproliferation； 6. Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) with a score of 0-2.
Exclusion criteria
1. Accompanied by cerebral hemorrhage； 2. Pregnancy； 3. Have a mental illness or other condition that cannot proceed as planned； 4. Severe arrhythmia, abnormal ECG (QT\>500ms). Early withdrawal from test criteria： Participants have the right to withdraw from the study at any time from the trial. Exit Criteria: 1. The subject or the subject's legally authorized representative requests to withdraw from the study; 2. Participant loss to follow-up. Doctor/Investigator required subjects to terminate the trial early: 1. Subjects who are unable to carry out follow-up treatment due to adverse events (serious irreversible organ function damage during treatment) who are judged by the investigator to be unsuitable for continuing the research; 2. The subject does not adhere to the protocol, such as the use of chemotherapy drugs, etc., which affects the effectiveness and safety judgment. For participants who withdrew early from the study (except subjects who were lost to follow-up), the reason for their early withdrawal should be recorded, and the time of the last study's medication/treatment should be recorded, and the examination items at the time of early withdrawal from the study should be completed at the last visit, if possible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission Rate | max 2 years | complete remission rate(CR rate), partial remission rate (PR rate) , no remission rate (NR rate) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence Rate | max 2 years | After complete remission, (1) naive cells appear in peripheral blood; (2) \>5% of bone marrow naive cells; (3) Extramedullary recurrence(refer to the 2014 NCCN guidelines). |
| Treatment-Related Mortality (TRM) | max 2 years | A death that is considered to be causally linked to a treatment |
| Overall Survival (OS) | max 2 years | Overall survival is a secondary endpoint that will be measured as time from the start of treatment until death from any cause, or the last date the patient was known to be alive |
| Event-Free Survival (EFS) | max 2 years | Event-free survival (EFS) was calculated from the time of informed consent until death, not achieving CR/CRi or relapse after CR/CRi. |
| Safety:Incidence and severity of adverse events | max 2 years | To evaluate the possible adverse events and deaths during treatment with selinexor in combination with HAD or CAG，mainly including liver toxicity, cardiotoxicity, bacterial infection, viral infection, fungal infection. |
Countries
China
Contacts
Primary ContactTao Wang
Outcome results
None listed